Context Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.1891 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 17.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Details
| Name | Context Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 15 |
| Founded | 2015 |
| Ipo Date | 2021-10-20 |
| Ceo | Martin Lehr |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 5.00 |
| Isin | US21077P1084 |
| Cusip | 21077P108 |
| Cik | 1842952 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Martin A. Lehr | Co-Founder, President, Chief Executive Officer and Director |
| Jennifer Minai-Azary | Chief Financial Officer and Treasurer |
| Alex C. Levit Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Christopher Beck M.B.A. | Senior Vice President of Operations |
| Jeffrey Liebman | Associate Director of Accounting |
| Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations |
| Dr. Karen Chagin M.D. | Chief Medical Officer |
Contact
| Address | 2001 Market Street, Suite 3915, Philadelphia, Pennsylvania 19103, United States |
| Phone | 267 225 7416 |
| Website | https://www.contexttherapeutics.com |